The results showed that the expression levels of KDM5A and KDM5C were negatively correlated with sensitivity to many pancreatic cancer-targeting or chemotherapeutic drugs, including axitinib and gemcitabine. The gene discussed is KDM5A; the disease is familial pancreatic carcinoma.